This site uses cookies. To learn more, please visit our Privacy Policy. By continuing to surf on our website, you consent to our use of cookies Close [X]
Nuclear medicine imaging is generally based on utilizing radioactive isotopes attached to specific molecules to examine biological processes, such as disease pathophysiology. These drugs can be administered orally, intravenously, or interstitially. Every radiopharmaceutical is designed to travel to a specific location in the body, and as soon as it reaches the site, it releases radioactive substances that kill the tumor cells. Radiopharmaceuticals can target various malignancies such as prostate cancer, heart disease, thyroid cancer, and others. These drugs can also be used as both therapies and diagnostics, known as 'theranostics. '
MARKET SCOPE
The "Global Radiopharmaceutical Theranostics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the radiopharmaceutical theranostics market with detailed market segmentation by radioisotope, source, approach, application, end user, and geography. The report provides key statistics on the market status of the leading radiopharmaceutical theranostics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
Based on radioisotope, the global radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64 and others.
On the basis of source, the market is bifurcated into nuclear reactors and cyclotrons.
On the basis of approach, the market is bifurcated into targeted therapeutic [Rx] and companion diagnostic [DX].
Based on application, the market is segmented into oncology, cardiology and others.
On the basis of end-users, the market is bifurcated into hospitals, academic & research institutes and others.
MARKET DYNAMICS Drivers:
Rise in the prevalence of cancer.
Increase in the availability of radioactive medicines by market players.
Rise in investments by key players for developing novel theranostics agents.
Rise in awareness of radiopharmaceuticals theranostics applications in disease treatment.
Restraints:
Stringent rules and regulations by the government.
Shortage of skilled professionals.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The radiopharmaceutical theranostics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the radiopharmaceutical theranostics market in these regions.
IMPACT OF COVID-19ON RADIOPHARMACEUTICAL THERANOSTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 pandemic has impacted the worldwide economy at various levels and has become a threat to global health. Due to the shutdown of manufacturing units, shortage in the supply of raw materials, and labor, there was a decline in the sales of market players. However, the radiopharmaceutical theranostics market stakeholders increased their R&D in nuclear medicine techniques, which was useful for functioning imaging of physiological processes at both cellular and molecular levels. Several advancements in radiolabeling methods also improved the radiopharmaceuticals accessibility for molecular imaging or radionuclide therapy, i.e., expected to surge the growth of the radiopharmaceutical theranostics market. Therefore, the pandemic has significantly affected the market's development and increased its growth.
Get more information on this report :
MARKET PLAYERS
The report covers key developments in the radiopharmaceutical theranostics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from radiopharmaceutical theranostics market are anticipated to have lucrative growth opportunities in the future with the rising demand for radiopharmaceutical theranostics in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the radiopharmaceutical theranostics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
Nihon Medi-Physics
Clarity Pharmaceuticals
Telix Pharmaceuticals
GE Healthcare
Theragnostics Ltd
ITM Isotopen Technologien München AG
Jubilant Pharma Limited
NuView Life Sciences
Lantheus Holdings, Inc.
Advanced Accelerator Applications
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Get more information on this report :
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Radiopharmaceutical Theranostics Market - By Radioisotope
1.3.2 Radiopharmaceutical Theranostics Market - By Source
1.3.3 Radiopharmaceutical Theranostics Market - By Approach
1.3.4 Radiopharmaceutical Theranostics Market - By Application
1.3.5 Radiopharmaceutical Theranostics Market - By End-user
1.3.6 Radiopharmaceutical Theranostics Market - By Region
1.3.6.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RADIOPHARMACEUTICAL THERANOSTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
6. RADIOPHARMACEUTICAL THERANOSTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. RADIOPHARMACEUTICAL THERANOSTICS - GLOBAL MARKET OVERVIEW
6.2. RADIOPHARMACEUTICAL THERANOSTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. RADIOPHARMACEUTICAL THERANOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - RADIOISOTOPE
7.1. OVERVIEW
7.2. RADIOISOTOPE MARKET FORECASTS AND ANALYSIS
7.3. TECHNETIUM-99
7.3.1. Overview
7.3.2. Technetium-99 Market Forecast and Analysis
7.4. GALLIUM-68
7.4.1. Overview
7.4.2. Gallium-68 Market Forecast and Analysis
7.5. IODINE-131
7.5.1. Overview
7.5.2. Iodine-131 Market Forecast and Analysis
7.6. IODINE-123
7.6.1. Overview
7.6.2. Iodine-123 Market Forecast and Analysis
7.7. 18F
7.7.1. Overview
7.7.2. 18F Market Forecast and Analysis
7.8. Y-90
7.8.1. Overview
7.8.2. Y-90 Market Forecast and Analysis
7.9. LUTETIUM (LU) 177
7.9.1. Overview
7.9.2. Lutetium (Lu) 177 Market Forecast and Analysis
7.10. COPPER (CU) 67
7.10.1. Overview
7.10.2. Copper (Cu) 67 Market Forecast and Analysis
7.11. COPPER (CU) 64
7.11.1. Overview
7.11.2. Copper (Cu) 64 Market Forecast and Analysis
7.12. OTHERS
7.12.1. Overview
7.12.2. Others Market Forecast and Analysis
8. RADIOPHARMACEUTICAL THERANOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - SOURCE
8.1. OVERVIEW
8.2. SOURCE MARKET FORECASTS AND ANALYSIS
8.3. NUCLEAR REACTORS
8.3.1. Overview
8.3.2. Nuclear Reactors Market Forecast and Analysis
8.4. CYCLOTRONS
8.4.1. Overview
8.4.2. Cyclotrons Market Forecast and Analysis
9. RADIOPHARMACEUTICAL THERANOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - APPROACH
9.1. OVERVIEW
9.2. APPROACH MARKET FORECASTS AND ANALYSIS
9.3. TARGETED THERAPEUTIC [RX]
9.3.1. Overview
9.3.2. Targeted Therapeutic [Rx] Market Forecast and Analysis
9.4. COMPANION DIAGNOSTIC [DX]
9.4.1. Overview
9.4.2. Companion Diagnostic [DX] Market Forecast and Analysis
10. RADIOPHARMACEUTICAL THERANOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
10.1. OVERVIEW
10.2. APPLICATION MARKET FORECASTS AND ANALYSIS
10.3. ONCOLOGY
10.3.1. Overview
10.3.2. Oncology Market Forecast and Analysis
10.4. CARDIOLOGY
10.4.1. Overview
10.4.2. Cardiology Market Forecast and Analysis
10.5. OTHERS
10.5.1. Overview
10.5.2. Others Market Forecast and Analysis
11. RADIOPHARMACEUTICAL THERANOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - END-USER
11.1. OVERVIEW
11.2. END-USER MARKET FORECASTS AND ANALYSIS
11.3. HOSPITALS
11.3.1. Overview
11.3.2. Hospitals Market Forecast and Analysis
11.4. ACADEMIC AND RESEARCH INSTITUTES
11.4.1. Overview
11.4.2. Academic and Research Institutes Market Forecast and Analysis
11.5. OTHERS
11.5.1. Overview
11.5.2. Others Market Forecast and Analysis
12. RADIOPHARMACEUTICAL THERANOSTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1 North America Radiopharmaceutical Theranostics Market Overview
12.1.2 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis
12.1.3 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Radioisotope
12.1.4 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Source
12.1.5 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Approach
12.1.6 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Application
12.1.7 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By End-user
12.1.8 North America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Countries
12.1.8.1 United States Radiopharmaceutical Theranostics Market
12.1.8.1.1 United States Radiopharmaceutical Theranostics Market by Radioisotope
12.1.8.1.2 United States Radiopharmaceutical Theranostics Market by Source
12.1.8.1.3 United States Radiopharmaceutical Theranostics Market by Approach
12.1.8.1.4 United States Radiopharmaceutical Theranostics Market by Application
12.1.8.1.5 United States Radiopharmaceutical Theranostics Market by End-user
12.1.8.2 Canada Radiopharmaceutical Theranostics Market
12.1.8.2.1 Canada Radiopharmaceutical Theranostics Market by Radioisotope
12.1.8.2.2 Canada Radiopharmaceutical Theranostics Market by Source
12.1.8.2.3 Canada Radiopharmaceutical Theranostics Market by Approach
12.1.8.2.4 Canada Radiopharmaceutical Theranostics Market by Application
12.1.8.2.5 Canada Radiopharmaceutical Theranostics Market by End-user
12.1.8.3 Mexico Radiopharmaceutical Theranostics Market
12.1.8.3.1 Mexico Radiopharmaceutical Theranostics Market by Radioisotope
12.1.8.3.2 Mexico Radiopharmaceutical Theranostics Market by Source
12.1.8.3.3 Mexico Radiopharmaceutical Theranostics Market by Approach
12.1.8.3.4 Mexico Radiopharmaceutical Theranostics Market by Application
12.1.8.3.5 Mexico Radiopharmaceutical Theranostics Market by End-user
12.2. EUROPE
12.2.1 Europe Radiopharmaceutical Theranostics Market Overview
12.2.2 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis
12.2.3 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Radioisotope
12.2.4 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Source
12.2.5 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Approach
12.2.6 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Application
12.2.7 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis - By End-user
12.2.8 Europe Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Radiopharmaceutical Theranostics Market
12.2.8.1.1 Germany Radiopharmaceutical Theranostics Market by Radioisotope
12.2.8.1.2 Germany Radiopharmaceutical Theranostics Market by Source
12.2.8.1.3 Germany Radiopharmaceutical Theranostics Market by Approach
12.2.8.1.4 Germany Radiopharmaceutical Theranostics Market by Application
12.2.8.1.5 Germany Radiopharmaceutical Theranostics Market by End-user
12.2.8.2 France Radiopharmaceutical Theranostics Market
12.2.8.2.1 France Radiopharmaceutical Theranostics Market by Radioisotope
12.2.8.2.2 France Radiopharmaceutical Theranostics Market by Source
12.2.8.2.3 France Radiopharmaceutical Theranostics Market by Approach
12.2.8.2.4 France Radiopharmaceutical Theranostics Market by Application
12.2.8.2.5 France Radiopharmaceutical Theranostics Market by End-user
12.2.8.3 Italy Radiopharmaceutical Theranostics Market
12.2.8.3.1 Italy Radiopharmaceutical Theranostics Market by Radioisotope
12.2.8.3.2 Italy Radiopharmaceutical Theranostics Market by Source
12.2.8.3.3 Italy Radiopharmaceutical Theranostics Market by Approach
12.2.8.3.4 Italy Radiopharmaceutical Theranostics Market by Application
12.2.8.3.5 Italy Radiopharmaceutical Theranostics Market by End-user
12.2.8.4 Spain Radiopharmaceutical Theranostics Market
12.2.8.4.1 Spain Radiopharmaceutical Theranostics Market by Radioisotope
12.2.8.4.2 Spain Radiopharmaceutical Theranostics Market by Source
12.2.8.4.3 Spain Radiopharmaceutical Theranostics Market by Approach
12.2.8.4.4 Spain Radiopharmaceutical Theranostics Market by Application
12.2.8.4.5 Spain Radiopharmaceutical Theranostics Market by End-user
12.2.8.5 United Kingdom Radiopharmaceutical Theranostics Market
12.2.8.5.1 United Kingdom Radiopharmaceutical Theranostics Market by Radioisotope
12.2.8.5.2 United Kingdom Radiopharmaceutical Theranostics Market by Source
12.2.8.5.3 United Kingdom Radiopharmaceutical Theranostics Market by Approach
12.2.8.5.4 United Kingdom Radiopharmaceutical Theranostics Market by Application
12.2.8.5.5 United Kingdom Radiopharmaceutical Theranostics Market by End-user
12.2.8.6 Rest of Europe Radiopharmaceutical Theranostics Market
12.2.8.6.1 Rest of Europe Radiopharmaceutical Theranostics Market by Radioisotope
12.2.8.6.2 Rest of Europe Radiopharmaceutical Theranostics Market by Source
12.2.8.6.3 Rest of Europe Radiopharmaceutical Theranostics Market by Approach
12.2.8.6.4 Rest of Europe Radiopharmaceutical Theranostics Market by Application
12.2.8.6.5 Rest of Europe Radiopharmaceutical Theranostics Market by End-user
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Radiopharmaceutical Theranostics Market Overview
12.3.2 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis
12.3.3 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Radioisotope
12.3.4 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Source
12.3.5 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Approach
12.3.6 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Application
12.3.7 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis - By End-user
12.3.8 Asia-Pacific Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Radiopharmaceutical Theranostics Market
12.3.8.1.1 Australia Radiopharmaceutical Theranostics Market by Radioisotope
12.3.8.1.2 Australia Radiopharmaceutical Theranostics Market by Source
12.3.8.1.3 Australia Radiopharmaceutical Theranostics Market by Approach
12.3.8.1.4 Australia Radiopharmaceutical Theranostics Market by Application
12.3.8.1.5 Australia Radiopharmaceutical Theranostics Market by End-user
12.3.8.2 China Radiopharmaceutical Theranostics Market
12.3.8.2.1 China Radiopharmaceutical Theranostics Market by Radioisotope
12.3.8.2.2 China Radiopharmaceutical Theranostics Market by Source
12.3.8.2.3 China Radiopharmaceutical Theranostics Market by Approach
12.3.8.2.4 China Radiopharmaceutical Theranostics Market by Application
12.3.8.2.5 China Radiopharmaceutical Theranostics Market by End-user
12.3.8.3 India Radiopharmaceutical Theranostics Market
12.3.8.3.1 India Radiopharmaceutical Theranostics Market by Radioisotope
12.3.8.3.2 India Radiopharmaceutical Theranostics Market by Source
12.3.8.3.3 India Radiopharmaceutical Theranostics Market by Approach
12.3.8.3.4 India Radiopharmaceutical Theranostics Market by Application
12.3.8.3.5 India Radiopharmaceutical Theranostics Market by End-user
12.3.8.4 Japan Radiopharmaceutical Theranostics Market
12.3.8.4.1 Japan Radiopharmaceutical Theranostics Market by Radioisotope
12.3.8.4.2 Japan Radiopharmaceutical Theranostics Market by Source
12.3.8.4.3 Japan Radiopharmaceutical Theranostics Market by Approach
12.3.8.4.4 Japan Radiopharmaceutical Theranostics Market by Application
12.3.8.4.5 Japan Radiopharmaceutical Theranostics Market by End-user
12.3.8.5 South Korea Radiopharmaceutical Theranostics Market
12.3.8.5.1 South Korea Radiopharmaceutical Theranostics Market by Radioisotope
12.3.8.5.2 South Korea Radiopharmaceutical Theranostics Market by Source
12.3.8.5.3 South Korea Radiopharmaceutical Theranostics Market by Approach
12.3.8.5.4 South Korea Radiopharmaceutical Theranostics Market by Application
12.3.8.5.5 South Korea Radiopharmaceutical Theranostics Market by End-user
12.3.8.6 Rest of Asia-Pacific Radiopharmaceutical Theranostics Market
12.3.8.6.1 Rest of Asia-Pacific Radiopharmaceutical Theranostics Market by Radioisotope
12.3.8.6.2 Rest of Asia-Pacific Radiopharmaceutical Theranostics Market by Source
12.3.8.6.3 Rest of Asia-Pacific Radiopharmaceutical Theranostics Market by Approach
12.3.8.6.4 Rest of Asia-Pacific Radiopharmaceutical Theranostics Market by Application
12.3.8.6.5 Rest of Asia-Pacific Radiopharmaceutical Theranostics Market by End-user
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Radiopharmaceutical Theranostics Market Overview
12.4.2 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis
12.4.3 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Radioisotope
12.4.4 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Source
12.4.5 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Approach
12.4.6 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Application
12.4.7 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis - By End-user
12.4.8 Middle East and Africa Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Radiopharmaceutical Theranostics Market
12.4.8.1.1 South Africa Radiopharmaceutical Theranostics Market by Radioisotope
12.4.8.1.2 South Africa Radiopharmaceutical Theranostics Market by Source
12.4.8.1.3 South Africa Radiopharmaceutical Theranostics Market by Approach
12.4.8.1.4 South Africa Radiopharmaceutical Theranostics Market by Application
12.4.8.1.5 South Africa Radiopharmaceutical Theranostics Market by End-user
12.4.8.2 Saudi Arabia Radiopharmaceutical Theranostics Market
12.4.8.2.1 Saudi Arabia Radiopharmaceutical Theranostics Market by Radioisotope
12.4.8.2.2 Saudi Arabia Radiopharmaceutical Theranostics Market by Source
12.4.8.2.3 Saudi Arabia Radiopharmaceutical Theranostics Market by Approach
12.4.8.2.4 Saudi Arabia Radiopharmaceutical Theranostics Market by Application
12.4.8.2.5 Saudi Arabia Radiopharmaceutical Theranostics Market by End-user
12.4.8.3 U.A.E Radiopharmaceutical Theranostics Market
12.4.8.3.1 U.A.E Radiopharmaceutical Theranostics Market by Radioisotope
12.4.8.3.2 U.A.E Radiopharmaceutical Theranostics Market by Source
12.4.8.3.3 U.A.E Radiopharmaceutical Theranostics Market by Approach
12.4.8.3.4 U.A.E Radiopharmaceutical Theranostics Market by Application
12.4.8.3.5 U.A.E Radiopharmaceutical Theranostics Market by End-user
12.4.8.4 Rest of Middle East and Africa Radiopharmaceutical Theranostics Market
12.4.8.4.1 Rest of Middle East and Africa Radiopharmaceutical Theranostics Market by Radioisotope
12.4.8.4.2 Rest of Middle East and Africa Radiopharmaceutical Theranostics Market by Source
12.4.8.4.3 Rest of Middle East and Africa Radiopharmaceutical Theranostics Market by Approach
12.4.8.4.4 Rest of Middle East and Africa Radiopharmaceutical Theranostics Market by Application
12.4.8.4.5 Rest of Middle East and Africa Radiopharmaceutical Theranostics Market by End-user
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Radiopharmaceutical Theranostics Market Overview
12.5.2 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis
12.5.3 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Radioisotope
12.5.4 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Source
12.5.5 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Approach
12.5.6 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Application
12.5.7 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By End-user
12.5.8 South and Central America Radiopharmaceutical Theranostics Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Radiopharmaceutical Theranostics Market
12.5.8.1.1 Brazil Radiopharmaceutical Theranostics Market by Radioisotope
12.5.8.1.2 Brazil Radiopharmaceutical Theranostics Market by Source
12.5.8.1.3 Brazil Radiopharmaceutical Theranostics Market by Approach
12.5.8.1.4 Brazil Radiopharmaceutical Theranostics Market by Application
12.5.8.1.5 Brazil Radiopharmaceutical Theranostics Market by End-user
12.5.8.2 Argentina Radiopharmaceutical Theranostics Market
12.5.8.2.1 Argentina Radiopharmaceutical Theranostics Market by Radioisotope
12.5.8.2.2 Argentina Radiopharmaceutical Theranostics Market by Source
12.5.8.2.3 Argentina Radiopharmaceutical Theranostics Market by Approach
12.5.8.2.4 Argentina Radiopharmaceutical Theranostics Market by Application
12.5.8.2.5 Argentina Radiopharmaceutical Theranostics Market by End-user
12.5.8.3 Rest of South and Central America Radiopharmaceutical Theranostics Market
12.5.8.3.1 Rest of South and Central America Radiopharmaceutical Theranostics Market by Radioisotope
12.5.8.3.2 Rest of South and Central America Radiopharmaceutical Theranostics Market by Source
12.5.8.3.3 Rest of South and Central America Radiopharmaceutical Theranostics Market by Approach
12.5.8.3.4 Rest of South and Central America Radiopharmaceutical Theranostics Market by Application
12.5.8.3.5 Rest of South and Central America Radiopharmaceutical Theranostics Market by End-user
13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
14. RADIOPHARMACEUTICAL THERANOSTICS MARKET, KEY COMPANY PROFILES
14.1. NIHON MEDI-PHYSICS
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. CLARITY PHARMACEUTICALS
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. TELIX PHARMACEUTICALS
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. GE HEALTHCARE
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. THERAGNOSTICS LTD
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. ITM ISOTOPEN TECHNOLOGIEN MüNCHEN AG
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. JUBILANT PHARMA LIMITED
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. NUVIEW LIFE SCIENCES
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. LANTHEUS HOLDINGS, INC.
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. ADVANCED ACCELERATOR APPLICATIONS
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments
15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
The List of Companies
1. Nihon Medi-Physics
2. Clarity Pharmaceuticals
3. Telix Pharmaceuticals
4. GE Healthcare
5. Theragnostics Ltd
6. ITM Isotopen Technologien München AG
7. Jubilant Pharma Limited
8. NuView Life Sciences
9. Lantheus Holdings, Inc.
10. Advanced Accelerator Applications
